ViaCell obtains worldwide exclusive license to patented oocyte cryopreservation technique.(Gamete Technology, Inc.)

From: BIOTECH Patent News | Date: August 1, 2003 | Copyright information

ViaCell, Inc. (Boston, MA) a clinical-stage biotechnology company developing cellular therapies, has obtained a worldwide exclusive license from Gamete Technology, Inc. (North Kingstown, RI) and Massachusetts General Hospital for use of patented technology to cryopreserve unfertilized human oocytes (eggs). The technology designed to help freeze, store and later fertilize oocytes is the result of an eight-year development effort led by Thomas Toth, M.D., Mehmet Toner, Ph.D., and Al...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

A HOPE TO FREEZE, BANK WOMEN'S EGGS BOSTON BIOTECH FIRM PLANS CLINICAL TRIALS
The Boston Globe ; A Boston biotechnology company using techniques developed at Massachusetts General Hospital said yesterday that it is close to commercializing a major step forward in reproductive technology: enabling women to freeze their unfertilized eggs for later use. ViaCell Inc., which has a thriving business
Boston Company That Freezes, Banks Women's Eggs Plans Clinical Trials.
Knight Ridder/Tribune Business News ; By Jeffrey Krasner, The Boston Globe Knight Ridder/Tribune Business News Aug. 13--A Boston biotechnology company using techni ... ues developed at Massachusetts ... globe (c) 2003, The Boston Globe. Distributed by Knight Ridder/Tribune Business News.
ViaCell and Genzyme announce collaboration agreement in diabetes.
BIOTECH Patent News ; ViaCell, Inc. (Cambridge, MA) and Genzyme Corporation (Cambridge, MA) announced that the two companies entered into a collaboration related to diabetes. Over the next 18 months Genzyme will conduct research to improve production and characterization of islet stem cells, and to undertake preclinical
PerkinElmer to acquire ViaCell in $300m deal
The Boston Globe ; PerkinElmer Inc., a Waltham company that sells an array of life sciences instruments and services, unveiled plans late yesterday to buy ViaCell Inc. of Cambridge for $300 million to bolster its genetics-screening business for pregnant women and newborn children. Although ViaCell is probably best
VIACELL TO ACQUIRE CEREBROTEC, CREATE NEUROSCIENCE DIVISION
The Boston Globe ; ViaCell Inc. of Boston is expected to announce today that it has acquired Cerebrotec, another privately held Boston firm that is developing new therapeutic products to help stroke patients. ViaCell will hire Cerebrotec's five researchers and set up a neuroscience division. The division, with lab
VIACELL/AMGEN SIGN COLLABORATION/LICENSE PACT.
Biotech Business ; ViaCell, Inc. Boston, has signed a collaboration and license agreement with Amgen Inc. in the field of cellular therapy that provides ViaCell with licenses to certain cellular growth factors and provides Amgen with the right to collaborate with ViaCell to develop and commercialize cellular therapy
STEM-CELL PLAN LINKS BIOTECHS GENZYME, VIACELL TARGET A CURE FOR JUVENILE DIABETES
The Boston Globe ; Stem-cell upstart Viacell Inc. and Genzyme Corp. are joining forces to develop a therapy they said has a chance of curing juvenile diabetes within years. The collaboration with Genzyme is a strong endorsement for Viacell, which went public in January. Terms of the deal between the Cambridge firms
Market looking good initially.(Business)
The Boston Herald ; Byline: BRETT ARENDS For Marc Beer, the window for taking his company public finally opened earlier this year. We had considered it two years ago, and decided it wasn't the right time - the market wasn't ready, said the CEO of Cambridge-based biotech ViaCell, Inc. yesterday. Yet ViaCell, which
MONEY IN THE BANK: SELLING CELLS; Eager to tap potential $1B market, cord-blood storers target moms.(ViaCord Blood Cord Service)
Advertising Age ; Byline: ALICE Z. CUNEO The only industry that can honestly say it has a once-in-a-lifetime offer is pushing into the ranks of the billion-dollar direct-to-consumer health-care marketplace. A number of the nation's cord-blood banks, which freeze blood from a placenta and umbilical cord to use in
VIACELL LICENSES PROTEIN FOR STROKE RECOVERY TREATMENT.
Biotech Business ; ViaCell Inc., Boston, a premier cellular therapy company, has obtained an exclusive worldwide license for dimerized fibroblast growth factor (dFGF), a novel protein developed by scientists at Massachusetts Institute of Technology (M.I.T with applications for the treatment of stroke and other